

Manuscript no. HAEMATOL/2011/049981 entitled “The HIV-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the multiple myeloma cells proliferation in vitro and in vivo”

Authors: Camille Bono, Lionel Karlin, Stephanie Harel, Enguerran Mouly, Sylvaine Labaume, Lionel Galicier, Sébastien Apcher, Hélène Sauvageon, Jean-Paul Fermand, Jean-Christophe Bories and Bertrand Arnulf

Information about the contributions of each person named as having participated in the study

1) Guarantor(s), i.e., person(s) who is (are) responsible for the integrity of the work as a whole:

- Jean-Christophe Bories, EA 3963, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, France, jc.bories@univ-paris.diderot.fr
- Bertrand Arnulf, EA 3963, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, et Département d’Immuno-hématologie, Hôpital St Louis, Paris, France Bertrand.arnulf@sls.aphp.fr
- Jean-Paul Fermand, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, et Département d’Immuno-hématologie, Hôpital St Louis, Paris, France jpfermand@yahoo.fr
- Camille Bono, EA 3963, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, France, camillebono@yahoo.fr

According to the International Committee of Medical Journal Editors (ICMJE) (http://www.icmje.org/ethical_1author.html): “*Authorship credit should be based on: 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3 Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship*”.

The guarantors of this manuscript confirm that all persons designated as authors qualify for authorship, and that each author has participated sufficiently in the work to take public responsibility for appropriate portions of the content.

2) Authors who participated in the **conception of the study**: Jean-Christophe Bories, Bertrand Arnulf, Camille Bono

3) **Design & Methods**. The following authors were responsible for specific investigations (please detail):

- Camille Bono and Sylvaine Labaume were responsible for the cell culture
- Camille Bono and Sébastien Apcher were responsible for proteasome experiment
- Camille Bono, Sylvaine L ionel Karlin and Stéphanie Harel were responsible for the cell proliferation and viability
- Camille Bono and Enguerran Mouly were responsible for the cytometry
- Camille Bono was responsible for the Western-Blot
- Camille Bono, Sylvaine Labaume were responsible for the generation of the U266-luc cells and for the human MM xenograft model

4) **Results**. The following authors were responsible for specific portions of the results, including figures and tables (please indicate the person responsible for each figure and each table):

- Camille Bono, Sylvaine Labaume, Lionel Karlin and Stéphanie Harel were responsible for the Figure 1
- Camille Bono, Sylvaine Labaume, Lionel Karlin and Stéphanie Harel were responsible for the Figure 2

- Camille Bono and Sylvaine Labaume were responsible for the Figure 3
- Camille Bono was responsible for the figure 4
- Camille Bono and Sylvaine Labaume were responsible for the Figure 5
- Camille Bono was responsible for the Figure 6

5) **Writing the manuscript.** The following authors were responsible for writing the manuscript:

- Camille Bono, EA 3963, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, France, camillebono@yahoo.fr
- Bertrand Arnulf, EA 3963, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, et Département d'Immuno-hématologie, Hôpital St Louis, Paris, France Bertrand.arnulf@sls.aphp.fr
- Jean-Christophe Bories, EA 3963, Univ Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Paris, France, jc.bories@univ-paris.diderot.fr

6) **Contributors Listed in Acknowledgments:**

L. GALICIER and H. SAUVAGEON ave contributed to the start of the study and have provided sample of patients and drugs.

This work was supported by grants from the Association pour la Recherche Contre le Cancer N° 3539 and 3750 and a grant from the Fondation de France N° 2004004116. C. Bono is a recipient of the Convention Industrielle de Formation par la REcherche (CIFRE) fellowship and from the Association pour la Recherche Contre le Cancer. L. Karlin was supported by the Association pour la Recherche Contre le Cancer.